Osteopore Ltd (osx) Logo

Osteopore Ltd (OSX)

___:___ · AUD

OSX Chart

OSX's Principal Activity is the medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. It also fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -51.39%
vs ASX 200 (1yr) -64.81%


Market Capitalisation
ASX Rank 1,554 of 2,295
Sector Rank 138 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies PAA / CGB / EMD
EPS -$0.018
DPS $0.00
NTA per share $0.08

Broker Consensus

OSX is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

Osteopore Limited (OSX) is an Australian and Singapore based medical technology company commercialising a range of products engineered to facilitate bone healing across range of therapeutic areas. The Group's patented technology fabricates micro-structured scaffolds for bone regeneration through 3D printing & bioresorbable material, bioresorbable scaffolds for regenerative bone healing.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office West Perth WA 6005
Website www.osteopore.com
Registry Link Market Services
Auditor Grant Thornton Audit Pty Ltd
Date Listed 23 Sep 2019

Upcoming Calendar (Forecasted)

Date Event
30/08/2021 Report (Interim)
25/02/2022 Report (Prelim)
24/03/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Stuart John Carmichael Non-Executive Director Dec 2019 Director Bio icon

Mr Stuart John Carmichael

Non-Executive Director

Mr Carmichael have 20 years of experience in the provision of corporate advisory services both within Australia and internationally. Mr Carmichael is a partner and director of Ventnor Capital Pty Ltd and Ventnor Securities Pty Ltd which specialises in the provision of corporate and financial advice to small cap ASX listed companies including capital raisings, initial public offerings, corporate restructures and mergers and acquisitions.

Mr Brett Sandercock Non-Executive Chairman,Non-Executive Director Jun 2019 Director Bio icon

Mr Brett Sandercock

Non-Executive Chairman,Non-Executive Director

Mr Sandercock was appointed Chief Financial Officer of Resmed Limited (NYSE: RMD, ASX: RMD) in January 2006. Previously he served as Resmed's Vice President of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004 Before joining ResMed, Mr Sandercock was Manager of Financial Accounting and Group Reporting at Norton Abrasives from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia. From 1989 to 1994, he worked at PriceWaterhouse Coopers in Sydney, specialising in audits of clients across distribution and manufacturing financial services, technology, and other industries.

Mr Geoffrey (Geoff) Richard Pocock Executive Director Jun 2019 Director Bio icon

Mr Geoffrey (Geoff) Richard Pocock

Executive Director

Mr Pocock has experience as a corporate advisor and strategy consultant advising companies on commercialisation and IP management, business development, mergers and acquisitions strategy and raising equity capital from private and public equity markets. Mr Pocock is currently the Principal of Polaris Consulting (WA) Pty Ltd, and was formerly the Managing Director of Hazer Group Ltd, an ASX-listed cleantech chemical engineering company, commercialising a novel low cost and low emission graphite and hydrogen production process initially developed by the University of Western Australia. Mr Pocock previously spent several years as a research scientist in the biopharmaceutical industry in Australia and the United Kingdom.

Professor Swee Hin Teoh Non-Executive Director Jun 2019 Director Bio icon

Professor Swee Hin Teoh

Non-Executive Director

Prof Teoh is the President's Chair, School of Chemical and Biomedical Engineering (SCBE). He holds a joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University. His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng - 1st Class Hon and PhD, Monash University), his research journey focused on translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechno induction through load bearing scaffolds for tissue regeneration and remodelling. Prof. Teoh's work on 3D printed scaffold led to him receiving the prestigious "Golden Innovation Award" at the Far East Economic Review, and the Institute of Engineers "Prestigious Engineering Achievement Award" in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for "Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore's profiled scientists in the book titled Singapore's Scientific Pioneers. Prof. Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits in as board of editors Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.

Mr Khoon Seng Goh Chief Executive Officer Sep 2018 Director Bio icon

Mr Khoon Seng Goh

Chief Executive Officer

Mr Goh has 30-year career spans both start-ups and global multinational corporations, with responsibilities in research and development, manufacturing, regional sales and marketing, and country management. Prior to joining Osteopore Mr Goh spent over 20 years with Medtronic plc (Medtronic plc is the world's largest medical device company) and Edwards Lifesciences Asia in various senior management roles. Mr Goh has been a Director of Osteopore Pte Ltd, since 2015 and has been involved in all aspects of the Company.

Ms Deborah Ho Company Secretary N/A
Carl Runde Chief Financial Officer N/A
Lim Jing Chief Technology Officer N/A

Director Interests

The current holdings of OSX directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Swee Hin Teoh 31/12/2020 7,030,309 N/A 1,500,000 N/A
Geoffrey (Geoff) Pocock 31/12/2020 N/A 168,539 1,200,000 N/A
Brett Sandercock 31/12/2020 155,039 N/A 500,000 N/A
Stuart Carmichael 31/12/2020 1 1,000,000 500,000 N/A
Khoon Seng Goh N/A N/A N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Feb 23, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
The Rain Maker Mgmt Pte Ltd 9,285,927 11.90%
Mr Michael Marcus Liew 5,932,785 7.60%
BNP Paribas Noms Pty Ltd <Drp> 5,241,740 6.72%
Ching-Yuan Huang 4,211,529 5.40%
The Rain Maker Mgmt Sdn Bhd 4,015,000 5.14%
Citicorp Nominees Pty Limited 3,479,199 4.46%
Ho-Chwan Investment Co Ltd 3,158,647 4.05%
Mr Hanry Yu 3,155,552 4.04%
Round Table Partners Berhad 1,894,875 2.43%
HSBC Custody Nominees (Australia) Limited 1,433,949 1.84%
Tan Siow Khoon 1,223,250 1.57%
J P Morgan Nominees Australia Pty Limited 982,618 1.26%
Mr Pak Lim Kong 858,326 1.10%
Altor Capital Management Pty Ltd <Altor Alpha Fund A/C> 633,019 0.81%
HSBC Custody Nominees (Australia) Limited i 542,453 0.70%
BNP Paribas Noms Pty Ltd <Uob Kay Hian Priv Ltd Drp> 526,698 0.67%
Dr Salim Cassim 290,575 0.37%
Mr Gary Thomas Cunningham & Mrs Lorilie Susan Cunningham <Gtc Superannuation Fund A/C> 277,000 0.35%
Ms Grace How Pei Yen 261,538 0.34%
Aris Nominees Pty Ltd <Shreeve Family A/C> 260,000 0.33%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 478 899 458 575 78 2,488

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Marcus Liew 23/02/2021 5,932,785 5.06
The Rain Maker MGMT Pte Ltd 23/02/2021 9,285,927 7.92
Goh Khoon Seng 23/02/2021 6,835,316 5.83
Teoh Swee Hin 23/02/2021 7,030,309 6.00
The Rain Maker MGMT SDN BHD 13/07/2021 10,268,345 8.76

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
13-07-21 The Rain Maker MGMT SDN BHD 3,032,582 11.3 8.76
16-12-20 The Rain Maker MGMT SDN BHD 1,985,000 15.1 11.34

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.40 30 June
Page Icon
OSX Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.